<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646786</url>
  </required_header>
  <id_info>
    <org_study_id>IDIL/2016/LJ-01</org_study_id>
    <nct_id>NCT03646786</nct_id>
  </id_info>
  <brief_title>Prospective Pilot Study of Multi-actor Tolerance Evaluation Using the VIRARE Device (VIrtual Reality Assisted Rehabilitation) in Visually Impaired Patients</brief_title>
  <acronym>VIRARE</acronym>
  <official_title>Prospective Pilot Study of Multi-actor Tolerance Evaluation Using the VIRARE Device (VIrtual Reality Assisted Rehabilitation) in Visually Impaired Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study aims to validate the relevance of a virtual reality tool (VIRARE: VIrtual REality
      Assisted Rehabilitation) in the assessment and rehabilitation of visually impaired subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dizziness felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nausea felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>headache felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>dazzle felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>watering of the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>eye burns felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain due to the mobilization of the eyeballs felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extraocular pain felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>diplopia</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>amaurosis</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fear</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>conformity of the session according to the patient point of view</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>unpleasantness of the session from the patient point of view</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difficulty of the session according to the patient point of view</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Willingness to continue the following tests according to the patient point of view</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cervical pain felt by the patient</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>oculomotricity of the patient according to the therapist</measure>
    <time_frame>Day 0</time_frame>
    <description>Rank: 0-missing, 1-insufficient, 2-medium, 3-suitable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>head movements of the patient according to the therapist</measure>
    <time_frame>Day 0</time_frame>
    <description>Rank: 0-missing, 1-insufficient, 2-medium, 3-suitable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>body movements of the patient according to the therapist</measure>
    <time_frame>Day 0</time_frame>
    <description>Rank: 0-missing, 1-insufficient, 2-medium, 3-suitable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>target tracking by the patient according to the therapist</measure>
    <time_frame>Day 0</time_frame>
    <description>0 = 0 target detected
1 or 2 targets detected
3 or 4 targets detected
5 targets detected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time lapse to find targets</measure>
    <time_frame>Day 0</time_frame>
    <description>minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The patient asked for a pause during the test</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The patient asked to permanently stop the tests</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The patient went to the right place during the 3rd test</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The patient has correctly performed the requested task</measure>
    <time_frame>Day 0</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Visual Impairment</condition>
  <arm_group>
    <arm_group_label>visually impaired patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Virtual reality tests</intervention_name>
    <description>The patient will complete 3 self-questionnaires and pass 3 exploratory tests of virtual reality:
10 minutes sitting test: detection of 5 targets in a 360 ° field of vision
10-minute stand-up motionless test: detection of 5 targets in a 360 ° field of view and placing ingredients of a recipe
Standing 10-minute test: the patient moves to the site of his mission, detection of 5 targets in a 360 ° field of vision and preparing a recipe</description>
    <arm_group_label>visually impaired patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient signed the consent form

          -  The patient is affiliated to a health insurance programme

          -  The patient presents ophthalmological or neurological pathologies with impact on
             visual function (retinopathy pigmentosa, macular dystrophy, glaucoma, age-related
             macular degeneration, cerebrovascular accident ...).

          -  The patient is visually impaired (visual acuity less than 3/10 of both eyes or
             concentric narrowing of the Goldmann binocular visual field or homonymous hemianopia)
             of category I or II of the WHO classification.

        Exclusion Criteria:

          -  The patient is participating in another study

          -  The patient is in an exclusion period determined by another study

          -  The patient is under safeguard of justice.

          -  The patient is under judicial protection.

          -  It is not possible to give the patient (or his/her trusted-person) informed
             information.

          -  The patient is pregnant or breastfeeding.

          -  The patient has a sensory or cognitive disability.

          -  The patient has difficulty moving.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc JEANJEAN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nîmes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luc JEANJEAN</last_name>
    <phone>+33(0)4.66.68.36.84</phone>
    <email>luc.jeanjean@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nimes University Hospital</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>+33 (0)4.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Luc JEANJEAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier Michel LUCAS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fanny MACAES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud COLAVITTI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Laurent</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>August 23, 2018</last_update_submitted>
  <last_update_submitted_qc>August 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Vision, Low</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

